Consensus Keros Therapeutics, Inc.

Stocks

KROS

US4923271013

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:04:54 2026-10-23 EDT			5-day change	1st Jan Change
11.16 ^USD	-1.67%		+4.97%	-45.04%

09-29	Keros Therapeutics Expects $20 Million Milestone Payment From Takeda	MT
09-29	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda	CI

Evolution of the Average Target: Keros Therapeutics, Inc.

Evolution of the Target Price: Keros Therapeutics, Inc.

Changes in Analyst Recommendations: Keros Therapeutics, Inc.

567204e073e.qkS94V3EBPsY6SGhth8SDL-QetuoMSsgm0CWE5w4aog.3Qf8smqwVJpZgkzHgkd0btPTP4jRY05QqHXmQ9IKLsvMafS0BaFQsC2CdA~60ab31453982ab0bdffd4ef6fad51bb7

Analysts' recommendations: Keros Therapeutics, Inc.

08-11	BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20	MT
11-12	Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating	MT
11-06	Wedbush Raises Price Target on Keros Therapeutics to $16 From $15, Keeps Neutral Rating	MT
25-06-10	BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32	MT
25-04-09	Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating	MT
25-01-21	Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight	MT
25-01-17	Wedbush Downgrades Keros Therapeutics to Neutral From Outperform	MT
25-01-16	Oppenheimer Cuts Price Target on Keros Therapeutics to $23 From $63, Maintains Outperform Rating	MT
24-12-23	Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating	MT
24-12-16	Guggenheim Downgrades Keros Therapeutics to Neutral From Buy	MT
24-12-12	BTIG Downgrades Keros Therapeutics to Neutral From Buy; Shares Plunge	MT
24-12-12	TD Cowen Downgrades Keros Therapeutics to Hold From Buy	MT
24-12-12	William Blair Downgrades Keros Therapeutics to Market Perform From Outperform	MT
24-12-12	Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating	MT
24-10-24	Cantor Fitzgerald Initiates Keros Therapeutics at Overweight	MT
24-10-16	Scotiabank Initiates Keros Therapeutics at Sector Outperform	MT
24-09-23	Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target	MT
24-06-25	Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target	MT
23-07-31	Wedbush Starts Keros Therapeutics at Outperform With $86 Price Target	MT
23-07-26	BofA Securities Initiates Keros Therapeutics With Buy Rating, $65 Price Target	MT
23-07-26	BofA Securities Starts Keros Therapeutics at Buy With $65 Price Target	MT
23-05-05	Piper Sandler Adjusts Keros Therapeutics' Price Target to $110 From $120, Keeps Overweight Rating	MT
23-02-14	Cowen Starts Keros Therapeutics at Outperform	MT
22-12-13	BTIG Adjusts Price Target on Keros Therapeutics to $105 From $95, Maintains Buy Rating	MT
22-10-18	Truist Securities Starts Keros Therapeutics at Buy With $100 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	KEROS THERAPEUTICS, INC.					+74.74%
	WUXI APPTEC CO., LTD.					+35.78%
	ARGENX SE					+28.93%
	LONZA GROUP AG					+10.89%
	IQVIA HOLDINGS INC.					+8.75%
	BEONE MEDICINES AG					+14.18%
	REVOLUTION MEDICINES, INC.					+37.21%
	CELLTRION, INC.					+37.85%
	WUXI BIOLOGICS (CAYMAN) INC.					+32.7%
	GENMAB A/S					+4.59%
	Average					+28.56%
	Weighted average by Cap.					+23.85%